Vaccination following exposure to the Delta or Omicron variants of SARS-CoV-2 is likely to affect the quality, quantity and duration of immune responses.
The government has sent a consignment list for supplying 80 lakh doses of Covishield to different consignees to Serum Institute of India, which will start the supply soon, an official said.
According to an official source, Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute, has written to the Health Ministry offering the doses worth Rs 410 crore free of cost.
Petitioner Dilip Lunwat, the petitioner, said his daughter, a medical student, had severe headaches and vomiting after taking the vaccine in 2021. She was taken to a hospital where doctors found bleeding in her brain.
Petitioner Dilip Lunwat has also made Microsoft founder Bill Gates whose foundation had partnered with the SII, the Union government, Maharashtra government and Drug Controller of India respondents to the plea.
This is for the first time that a booster dose that is different from the one used for primary vaccination against Covid has been allowed in the country.
This is for the first time that a booster dose that is different from the one used for primary vaccination against Covid has been allowed in the country.
This is a remarkable feat, considering that all the vaccine doses administered in the country are made locally
The pharma regulator has approved the first mix-and-match of COVID-19 vaccines in India, but the final say-so lies with the government
The Serum Institute has produced more than one billion doses of Covishield -- its version of the AstraZeneca jab -- and is a major supplier to the Covax global inoculation programme for poorer countries.
The heat-tolerant COVID-19 vaccine candidate can be stored at 37 degrees Celsius for four weeks and at 100 degrees Celsius for up to 90 minutes.
New Delhi, Apr 12 Vaccine major Serum Institute of India (SII) has appealed to the government to reduce the gap between the second and booster dose..
The inventories at the private CVCs would be verified by SII representatives and the claim would then be processed on the basis of their approval.
A daily round-up of the most interesting articles to help jump-start the day.
While prices for the Covishield doses were brought down from Rs 600 a shot, Covaxin was slashed from Rs 1,200.
"In 10-14 days, Covovax can be available on CoWin at about Rs 900 plus tax," the SII chief executive said.
Private healthcare providers struggling to use up their stocks of Covishield and Covaxin shots are showing no enthusiasm for the Corbevax vaccination of children.
As the efficacy trials of the intranasal COVID-19 vaccine from Bharat Biotech begin this week, there are hopes that if successful, such a vaccine may finally bring the pandemic to an end
Unvaccinated tennis player Novak Djokovic has said that though he is not against COVID-19 vaccines, he will skip tournaments if compelled to take the jab.
As most vaccine beneficiaries prefer to line up at government hospitals, private hospitals now want the government to buy the doses. Of the nearly 175 crore vaccine doses administered, less than 5 percent have been in private hospitals
A sum of Rs 35,000 crore was originally proposed to be spent on COVID vaccination as part of 2021-22 budget which was later revised to Rs 39,000 crore. Response to an RTI query has revealed that the government has spent majority of the amount
Private hospitals were slated to be an important partner in the COVID19 vaccination drive launched in January, 2021 but barring a few initial months, their role in the massive campaign has been negligible as high prices of vaccines at private centres has kept people away.
A daily round-up of the most interesting articles to help jump-start the day.
The Drugs Controller General of India’s (DCGI) approval came after the Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) on January 19 recommended granting regular market approval to the Serum Institute of India’s (SII’s) Covishield and Bharat Biotech’s Covaxin for use in adult population subject to certain conditions.
According to official sources, the National Pharmaceutical Pricing Authority (NPPA) has been directed to start working towards capping the price to make the vaccines affordable.